News | September 03, 2014

Research at Jobst Vascular Institute Examines Safety and Effectiveness of Stents for Veins


September 3, 2014 — Jobst Vascular Institute is conducting pioneering research that looks at using stents to treat blocked veins. For years, stents have been used to treat narrowed or blocked arteries; however none are specifically designed for use in veins. The Cook Medical VIVO clinical research study aims to determine the safety and effectiveness of the Zilver vena venous self-expanding stent in the treatment of vein obstructions. Jobst Vascular Institute is the second center in the country to enroll a patient in the VIVO clinical research study.

“Veins differ greatly from arteries and require a different approach when treating blockages,” said Anthony Comerota, M.D., one of two global principal investigators in the VIVO clinical research study. “While arteries are muscular and under high pressure as they deliver blood throughout the body, veins are low-pressure vessels that return blood to the heart. When obstructed, they require stent characteristics different from those required by an artery.”

Vein obstruction or iliofemoral venous outflow obstruction is a blockage or narrowing of the major veins draining blood from the leg. It causes leg pain, throbbing, swelling and skin discoloration in the legs. It may also be associated with deep vein thrombosis, a blood clot in the leg. Patients are currently treated only with compression stockings or by elevating the leg. Some patients may be taking blood thinners.

“This is an important trial, which may expand the options for treating diseased veins,” said Comerota.

The Zilver vena venous self-expanding stent is an investigational device that is not approved for sale in the United States.

For more information: www.promedica.org/jobst, www.cookmedical.com


Related Content

News | Cardiovascular Clinical Studies

May 6, 2026 — Image Analysis Group (IAG), a global imaging CRO headquartered in London, U.K., and HeartcoR Solutions ...

Home May 06, 2026
Home
News | Cardiovascular Clinical Studies

April 9, 2026 — Mount Sinai researchers have created an analytic tool using machine learning that can predict ...

Home April 14, 2026
Home
News | Cardiovascular Clinical Studies

April 13, 2026 —The American Heart Association (AHA) has granted Case Western Reserve University the Rapid Impact ...

Home April 13, 2026
Home
News | Cardiovascular Clinical Studies

April 2, 2026 — Iterative Health and US Heart & Vascular (USHV) have announced a strategic partnership to advance ...

Home April 02, 2026
Home
News | Cardiovascular Clinical Studies

March 4, 2026 — UltraSight, a provider of AI-guided cardiac imaging workflows, has announced Late-Breaking clinical ...

Home March 04, 2026
Home
News | Cardiovascular Clinical Studies

Feb. 9, 2026 — HTA and MedAxiom have opened applications for the 2026 HeartX program, a cardiovascular-focused ...

Home February 18, 2026
Home
News | Cardiovascular Clinical Studies

Jan. 5, 2026 — Medera Inc., a clinical-stage biopharmaceutical company focused on targeting cardiovascular diseases by ...

Home January 05, 2026
Home
News | Cardiovascular Clinical Studies

Nov. 10, 2025 —Genomics, a science-led techbio company, has today announced new research that suggests polygenic risk ...

Home November 12, 2025
Home
News | Cardiovascular Clinical Studies

Oct. 21, 2025 – AskBio Inc., a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG ...

Home October 21, 2025
Home
News | Cardiovascular Clinical Studies

Aug. 25, 2025 — Merck, known as MSD outside of the United States and Canada, has announced that new clinical trial and ...

Home August 25, 2025
Home
Subscribe Now